Document and Entity Information Document Information [Table] Document Information [Line Items] Document and Entity Information Document Type Document Quarterly Report Current Fiscal Year End Date Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Balance Sheets Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalent Cash and cash equivalents Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits. Prepaid Expense, Security Deposits, and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Accrued Liabilities and Interest, and Employee-Related Liabilities, Current Accrued expenses Total accrued expenses Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non-current liabilities: Fair value of warrant liabilities which are expected to be settled after one year or the normal operating cycle, if longer. Warrant Liability, Noncurrent Warrant liability, ending balance Warrant liability, beginning balance Warrant liability Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 6) Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding Common Stock, Value, Issued Common stock - $0.0001 par value, 70,000,000 shares authorized, 42,606,152 and 27,199,139 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Equity, Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Number of preferred shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Number of common shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Statements of Operations Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Operating loss Nonoperating Income (Expense) [Abstract] Other income (expense): Investment Income, Interest Interest income Represents the charge against earnings during the period for transaction costs related to the issuance of shares. Financing Costs from Issuance of Shares Other financing costs Amount of gain (loss) from changes in fair value of warrant liabilities. Gain (Loss) on Changes in Fair Value of Warrant Liability Change in fair value of warrants Nonoperating Income (Expense) Total other income (expense), net Net loss Net loss Net loss No definition available. Disclosure of Earnings Per Share, Basic and Diluted [Abstract] Net loss per share Earnings Per Share, Basic Basic (dollars per share) Basic net loss per common share Earnings Per Share, Diluted Diluted (dollars per share) Diluted net loss per common share Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted-average number of common shares used in computing net loss per share Weighted Average Number of Shares Outstanding, Basic Basic Weighted-average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Diluted Denominator for diluted net loss per share Statements of Changes in Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to the April 2026 Canaccord Equity Offering and Warrant Issuance. April 2026 Canaccord Equity Offering and Warrant Issuance [Member] April 2026 Canaccord Equity Offering and Warrant Issuance Represents information pertaining to the May 2026 Canaccord Equity Offering and Warrant Issuance. May 2026 Canaccord Equity Offering and Warrant Issuance [Member] May 2026 Canaccord Equity Offering and Warrant Issuance Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in Stockholders' Equity (Deficit) Shares, Issued Balance, shares Balance, shares Equity impact of the value of new stock issued under terms of an equity distribution agreement during the period, net of issuance costs. Equity Distribution Agreement, Value of Stock Issued During Period, Net of Issuance Costs Issuance of common stock, pursuant to Equity Distribution Agreement, net of issuance costs Shares of stock issued during the period under terms of an equity distribution agreement. Stock Issued During Period, Shares, Equity Distribution Agreement Issuance of common stock, pursuant to Equity Distribution Agreement, net of issuance costs, shares Value of shares of stock issued attributable to registered underwritten offering, net of issuance costs and warrant liability. Issuance of Common Stock and Warrants under Registered Underwritten Offering, Net of Issuance Costs And Warrant Liability, Value Issuance of common stock and warrants under registered underwritten offering, net of issuance costs and warrant liability Number of shares and warrants issued during the period as a result of a registered underwritten offering, net of issuance costs and warrant liability. Issuance of Common Stock and Warrants under Registered Underwritten Offering, Net of Issuance Costs And Warrant Liability, Shares Issuance of common stock and warrants under registered underwritten offering, net of issuance costs and warrant liability, shares Equity impact of the value of new stock and warrants issued during the period under registered direct offering, net of issuance costs. Issuance of Common Stock and Warrants under Registered Direct Offering, Net of Issuance Costs, Value Issuance of common stock and warrants under registered offering, net of issuance costs Number of new stock and warrants issued during the period under registered direct offering, net of issuance costs. Issuance of Common Stock and Warrants under Registered Direct Offering, Net of Issuance Costs, Shares Issuance of common stock and warrants under registered offering, net of issuance costs, shares Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Options exercised Exercise of stock options, shares APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Stock-based compensation expense Statements of Cash Flows Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Fair Value Adjustment of Warrants Change in fair value of warrant liability Change in fair value of warrants Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash flows from financing activities: The net cash inflow from the issuance of common stock and warrants. Proceeds from Issuance of Common Stock and Warrants, Net Proceeds from issuance of common stock, and warrants, net Proceeds from Stock Options Exercised Proceeds from exercise of common stock options Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Nature of Business, Going Concern and Management's Plans Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Business, Going Concern and Management's Plan Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Prepaid Expenses and Other Current Assets The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block] Prepaid Expenses and Other Current Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Equity Equity [Text Block] Stockholders' Equity Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Income Taxes Income Tax Disclosure [Text Block] Income Taxes Segment Information Segment Reporting Disclosure [Text Block] Segment Information Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting [Text Block] Basis of Presentation of Interim Unaudited Financial Statements Use of Estimates, Policy [Policy Text Block] Use of Estimates Earnings Per Share, Policy [Policy Text Block] Basic and Diluted Net Income per Share Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Disclosure of accounting policy for issuance costs associated with equity issuances. Issuance Costs Associated with Equity Issuances [Policy Text Block] Issuance Costs Associated with Equity Issuances Derivatives, Policy [Policy Text Block] Liability Classified Common Stock Warrants Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Research, Development, and Computer Software, Policy [Policy Text Block] Research and Development Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Fair Value, Recurring and Nonrecurring [Table] Financial Instrument [Axis] Financial Instruments [Domain] Represents information pertaining to October 2023 Canaccord Warrants. Canaccord Warrants, October 2023 [Member] October 2023 Canaccord Warrants Represents information pertaining to April 2026 Canaccord Warrants. Canaccord Warrants, April 2026 [Member] April 2026 Canaccord Warrants Represents information pertaining to May 2026 Canaccord Warrants. Canaccord Warrants, May 2026 [Member] May 2026 Canaccord Warrants Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of quantitative information regarding Level 3 fair value measurements inputs Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Prepaid Expenses and Other Current Assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Stockholders' Equity Tabular disclosure of changes in common stock warrant liabilities. Schedule of Changes in Common Stock Warrant Liabilities [Table Text Block] Schedule of changes in common stock warrant liabilities Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of common stock warrants outstanding Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of shares excluded from the computation of diluted weighted-average shares outstanding Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment information Stock, Class of Stock [Table] Class of Stock [Line Items] Stockholders' Equity Summary of Significant Accounting Policies No definition available. Nature of Business and Liquidity [Abstract] Nature of Business and Management's Plans Number of patients in clinical study. Number of Patients in Clinical Study Number of patients in clinical study Revenue from Contract with Customer, Excluding Assessed Tax Revenue Substantial Doubt about Going Concern, within One Year [true false] Represents information pertaining to the October 2023 Canaccord Equity Offering and Warrant Issuance. October 2023 Canaccord Equity Offering and Warrant Issuance [Member] October 2023 Canaccord Equity Offering and Warrant Issuance Canaccord Warrants Cash, FDIC Insured Amount Cash balances at financial institutions, federally insured limit Stock Issued During Period, Shares, New Issues Number of shares issued Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of shares which may be purchased with warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Term of award (in years) Stock option contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Measurement Basis [Axis] Portion at Fair Value Measurement [Member] Reported Value Measurement [Member] Carrying Value Estimate of Fair Value Measurement [Member] Fair Value Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 3 [Member] Level 3 Assets, Fair Value Disclosure [Abstract] Assets: Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total assets measured and recorded at fair value Liabilities, Fair Value Disclosure [Abstract] Liabilities: Liabilities, Fair Value Disclosure Total liabilities measured and recorded at fair value Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Exercise Price [Member] Exercise price Measurement Input, Share Price [Member] Closing stock price Measurement Input, Price Volatility [Member] Volatility Measurement Input, Expected Term [Member] Term (time to expiration in years) Expected life (years) Measurement Input, Risk Free Interest Rate [Member] Risk-free rate Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurements Warrants and Rights Outstanding, Measurement Input Warrants, measurement input Class of Warrant or Right, Outstanding Ending balance Beginning balance Number of warrants Warrants and Rights Outstanding, Term Warrant term Term of warrants Period between issuance and vesting of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Warrants and Rights Outstanding, Vesting Period Warrants, vesting period Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research and Development Expense, Current Prepaid clinical expenses Other Prepaid Expense, Current Prepaid other Prepaid Insurance Prepaid Insurance Security Deposit Security deposits Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical liabilities. Accrued Clinical Liabilities, Current Accrued clinical expenses Employee-related Liabilities, Current Payroll and related benefits Accrued Professional Fees, Current Accrued professional fees and other Other Commitments [Table] Location, Statement of Income, Balance [Axis] Other Commitments [Line Items] Commitments and Contingencies Lease, Cost [Abstract] Leases Number of short-term leases. Number of Short-Term Leases Number of short term leases Operating Lease, Expense Rental expense Deferred Compensation Arrangements [Abstract] Employment Agreements The maximum aggregate severance payments payable to executive officers under the terms of employment agreements. Maximum Aggregate Severance Payments Maximum aggregate severance payments Number of classes of stock designated. Number of classes of stock designated Number of classes of stock designated The maximum number of shares permitted to be issued by an entity's charter and bylaws. Common Stock And Preferred Stock, Shares Authorized Number of common and preferred shares authorized Number of vote for each share of common stock. Number of Votes for Each Share of Common Stock Number of vote for each share of common stock Represents information pertaining to registered direct offering. Registered Direct Offering [Member] Registered direct offering Represents information pertaining to securities purchase agreement. Securities Purchase Agreement [Member] Securities Purchase Agreement Represents information pertaining to Stock Subscription Agreements. Stock Subscription Agreements [Member] Stock Subscription Agreements Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to Placement Agent Warrants. Placement Agent Warrants [Member] Placement Agent Warrants Measurement Input, Expected Dividend Rate [Member] Dividend rate Share Price Offering price per share Offering price per share or per unit of warrants or rights. Class of Warrant or Right, Offering Price Offering price of warrants Sale of Stock, Consideration Received on Transaction Net proceeds from the offering Payments of Stock Issuance Costs Issuance costs Offering costs Warrants and Rights Outstanding Aggregate fair value of warrants outstanding Value of stock issued during the period upon the exercise of warrants. Stock Issued During Period, Value, Exercise of Warrants Exercise of pre-funded common stock warrants Represents information pertaining to the February 2025 ThinkEquity Underwritten Offering and Warrant Issuance. February 2025 ThinkEquity Underwritten Offering and Warrant Issuance [Member] February 2025 ThinkEquity Underwritten Offering and Warrant Issuance Represents information pertaining to ThinkEquity Warrants. ThinkEquity Warrants [Member] ThinkEquity Warrants The number of units authorized for issuance. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at a per unit price. Sale of Stock, Number of Units Authorized for Issuance Number of units authorized to be issued Number of shares included in each unit. Number of Shares Included in Each Unit Number of common shares included in each unit Number of warrants included in each unit. Number of Warrants Included in Each Unit Number of warrants included in each unit Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares into which each warrant may be converted Shares Issued, Price Per Share Price per unit The gross proceeds from the additional capital contribution to the entity through the issuance of units. Each unit consists of one share of common stock, par value $0.0001 per share, and one warrant to purchase one share of the Company stock. Gross Proceeds from Issuance of Units Gross proceeds from issuance of units Number of warrants exercised. Class of Warrant or Right, Number of Warrants Exercised Number of warrants exercised No definition available. Rollforward of Common Stock Warrant Liability [Abstract] Roll-forward of the Common Stock Warrant Liability Represents information pertaining to warrants classified as equity. Warrants Classified as Equity [Member] IPO warrants Number of warrants issued during the period. Number of Warrants Issued During the Period Granted Number of warrants issued during the period Percentage of exercise price to the share offering price. Percentage of Exercise Price to the Share Offering Price Percentage of exercise price to the share offering price Sale of Stock, Number of Shares Issued in Transaction Number of shares issued Sale of Stock, Consideration Received Per Transaction Gross proceeds from the offering The amount of underwriter discount fees and third party costs. Underwriter Discount Fees and Third Party Costs Underwriter discounts fees and third party costs The amount of underwriter discount fees and third party costs recorded to other financing costs. Underwriter Discount Fees and Third Party Costs Recorded to Other Financing Costs Underwriter discount fees and third party costs recorded to other financing costs The amount of underwriter discount fees and third party costs recorded to additional paid-in capital. Underwriter Discount Fees and Third Party Costs Recorded Additional Paid-In Capital Underwriter discount fees and third party costs recorded to additional paid-in capital Represents information pertaining to ThinkEquity Warrants expiring on February 4, 2030. Think Equity Warrants, Expiration February 4, 2030 [Member] ThinkEquity warrants, Expiration February 4, 2030 Represents information pertaining to warrants classified as liabilities expiring on November 2, 2028. Warrants Classified as Liabilities, Expiration November 2, 2028 [Member] Canaccord warrants, Expiration November 2, 2028 Represents information pertaining to Placement Agent Warrants expiring on October 14, 2030. Placement Agent Warrants, Expiration October 14, 2030 [Member] Placement Agent Warrants, Expiration October 14, 2030 Represents information pertaining to Placement Agent Warrants expiring on October 28, 2030. Placement Agent Warrants, Expiration October 28, 2030 [Member] Placement Agent Warrants, Expiration October 28, 2030 Represents information pertaining to Canaccord Warrants expiring on October 8, 2031. Canaccord Warrants, Expiration October 8, 2031 [Member] April 2026 Canaccord Warrants, Expiration October 8, 2031 Represents information pertaining to Canaccord Warrants expiring on May 18, 2032. Canaccord Warrants, Expiration May 18, 2032 [Member] May 2026 Canaccord Warrants, Expiration May 18, 2032 The number of warrants converted in a noncash (or part noncash) transaction. Conversion of Warrants, Number of Warrants Converted Exercised or Expired Represents information pertaining to the December 2024 ATM Equity Offering. December 2024 At the Market Equity Offering [Member] December 2024 ATM The authorized value of common shares which may be sold under the terms of the At the Market (ATM) Equity Offering. At the Market Equity Offering, Common Stock, Authorized Value Aggregate offering price The gross proceeds from the additional capital contribution to the entity through the issuance of common stock. Gross Proceeds from Issuance of Common Stock Gross proceeds from issuance of common shares Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Pertaining to the 2018 Equity Incentive Plan. 2018 Plan Represents information pertaining to the Company's 2019 Equity Incentive Plan. 2019 Plan Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares available for future grants Share-Based Payment Arrangement, Expense Stock-based compensation expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options outstanding, ending balance Options outstanding, beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Options forfeited/canceled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options exercisable, ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options outstanding, ending balance (in dollars per share) Options outstanding, beginning balance (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options forfeited/canceled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options exercisable, ending balance (in dollars per share) No definition available. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract] Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Options outstanding Amount by which the current fair value of the underlying stock exceeds the exercise price of options expired during the period. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period, Intrinsic Value Options expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Options exercisable Restricted Stock [Member] Restricted Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Options, weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Net Loss Per Share Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net loss per share - Basic: No definition available. Earnings Per Share, Basic, Numerator [Abstract] Numerator No definition available. Earnings Per Share, Basic, Denominator [Abstract] Denominator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Net loss per share - Diluted: No definition available. Earnings Per Share, Diluted, Numerator [Abstract] Numerator Net Income (Loss) Available to Common Stockholders, Diluted Numerator for diluted net loss per share No definition available. Earnings Per Share, Diluted, Denominator [Abstract] Denominator Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Loss Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share Income Tax Expense (Benefit) Income tax benefit (expense) Unrecognized Tax Benefits, Period Increase (Decrease) Liability for uncertain tax positions Income Tax Examination, Penalties and Interest Accrued Accrued interest or penalties Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Domain] Represents information pertaining to a single reportable segment. Single Reportable Segment [Member] Single reportable segment Segment Reporting Information [Line Items] Segment Information Number of Reportable Segments Number of segments The amount of program expenses related to clinical-stage product candidates. Program Expenses Related to Clinical-Stage Product Candidates Program expenses related to clinical-stage product candidates The amount of program expenses related to preclinical and discovery programs. Program Expenses Related to Preclinical and Discovery Programs Program expenses related to preclinical and discovery programs The amount of program expenses related to clinical manufacturing candidates. Program Expenses Related to Clinical Manufacturing Candidates Program expenses related to clinical manufacturing candidates Labor and Related Expense Personnel-related expenses (including stock-based compensation) General and administrative expenses classified as professional and consultant fees. General and Administrative Expense, Professional and Consultant Fees General and administrative professional and consultant fees Segment Reporting, Other Segment Item, Amount Other segment items Other Noncash Income (Expense) Other non-cash income (expense) items Segment Reporting, Other Segment Item, Composition, Description Represents information pertaining to Maria Maccecchini. Maria Maccecchini [Member] Maria Maccecchini Represents information pertaining to Mark White. Mark White [Member] Mark White